Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents New Data at ESHRE 2021 Supporting the Use of Rekovelle (follitropin delta) for Individualized Fertility Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV"}]

    Find Clinical Drug Pipeline Developments & Deals for Follitropin alfa

    Menu

    Follitropin alfa

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ferring Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ferring Presents New Data at ESHRE 2021 Supporting the Use of Rekovelle (follitropin delta) for Individualized Fertility Treatment

              Details:

              New study demonstrates that individualised dosing with Rekovelle® (follitropin delta) was comparable to conventional dosing with follitropin alfa in terms of ongoing pregnancy rate in a broad Asian population.

              Lead Product(s): Follitropin

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Rekovelle

              Highest Development Status: Phase IV Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY